Market Overview

UPDATE: Deutsche Bank Raises WuXi PharmaTech's PT

Related WX
Top 4 Mid-Cap Stocks In The Medical Laboratories & Research Industry With The Lowest PEG Ratio
WuXi PharmaTech Subsidiary Submits Application To The National Equities Exchange And Quotations In China to List On The New Third Board
Update: WuXi PharmaTech Acquires NextCODE Health And Raises Guidance (Seeking Alpha)

According to a research report published this morning, Deutsche Bank has increased WuXi PharmaTech's (NYSE: WX) PT from $16 to $17.

In the report, Deutsche Bank said, "WX reported another strong quarter, beating street consensus and guidance on top line and EPS. While management reaffirmed guidance for the full year, we think guidance revision is likely in 3Q12 due to 65% and 109% yoy growth in backlogs for service and manufacturing, respectively. We do not foresee operating leverage in the near term due to RMB appreciation and labour cost inflation."

Deutsche Bank maintains its Buy rating on WuXi PharmaTech, which closed Friday at $14.68.

Latest Ratings for WX

Nov 2014JefferiesDowngradesBuyHold
Oct 2013JefferiesMaintainsBuy
Aug 2013JefferiesMaintainsBuy

View More Analyst Ratings for WX
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (WX)

Around the Web, We're Loving...

Get Benzinga's Newsletters